• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SOPHiA GENETICS Launches MSK-IMPACT® powered with SOPHiA DDM™ at AMP 2024

    11/21/24 5:30:00 AM ET
    $SOPH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SOPH alert in real time by email

    Launch of new application enables global access to highly recognized solid tumor profiling assay

    BOSTON and ROLLE, Switzerland, Nov. 21, 2024 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native healthcare technology leader in data-driven medicine, announced the global launch of MSK-IMPACT® powered with SOPHiA DDM™ today from the Association for Molecular Pathology (AMP) Annual Meeting. This innovative solution provides organizations worldwide with the opportunity to benefit from Memorial Sloan Kettering Cancer Center (MSK)'s best-in-class comprehensive genomic profiling (CGP) application on the SOPHiA DDM™ Platform with high accuracy and efficiency.

    SOPHiA GENETICS Logo (PRNewsfoto/SOPHiA GENETICS)

    "The launch of MSK-IMPACT® powered with SOPHiA DDM™ is another major milestone in our journey to expand access to precision oncology globally and demonstrates our commitment to democratizing data-driven medicine," said Philippe Menu, M.D., PhD., Chief Product Officer and Chief Medical Officer, SOPHiA GENETICS. "Following the successful launch of MSK-ACCESS® powered with SOPHiA DDM™ earlier this year, we are incredibly excited to further build on our excellent collaboration with MSK. Launching this application is a powerful step in our vision to decentralize access to advanced tumor profiling technologies, making these capabilities more widely available, especially in underserved populations."

    Kojo S. J. Elenitoba-Johnson, M.D., Chair of the Department of Pathology and Lab Medicine at MSK, added, "We share a vision with SOPHiA GENETICS to advance precision medicine and to make our leading tests more accessible to patients around the world."

    Through MSK-IMPACT® powered with SOPHiA DDM™, organizations can process more precise oncology analysis by enhancing the accuracy of somatic mutation detection, including in genes that are highly relevant for the current pharmaceutical industry R&D pipelines, such as MTAP. The matched tumor-normal analysis approach allows clinicians and researchers to detect somatic mutations more confidently, minimizing the risk of misclassifying germline variants as tumor-specific. Additionally, institutions benefit from the global collective intelligence created by SOPHiA GENETICS' network, allowing users to contribute to and draw from a continuously evolving base of real-world data and insights from diverse populations.

    SOFIVA GENOMICS, a leading molecular diagnostics company in Taiwan, is among the first to adopt this application. The company initially partnered with SOPHiA GENETICS in 2022 to utilize the SOPHiA DDM™ Homologous Recombination Deficiency (HRD) Solution. Now, SOFIVA GENOMICS is expanding its tumor profiling capabilities by adding MSK-IMPACT® powered with SOPHiA DDM™ alongside the liquid biopsy test MSK-ACCESS® powered with SOPHiA DDM™.  

    Chia-Cheng Hung, General Manager, SOFIVA GENOMICS, commented, "Our partnership with SOPHiA GENETICS has greatly enhanced our ability to provide localized, highly accurate genomic testing. Access to this advanced technology enables us to bring advanced, trusted capabilities and further our progress on cancer research in Taiwan."

    MSK-IMPACT® powered with SOPHiA DDM™ enables a more efficient workflow, with the entire process from DNA extraction to final report taking approximately five days. Clinicians and researchers benefit from access to OncoKB™, MSK's Precision Oncology Knowledge Base, which further enhances the interpretive power of the SOPHiA DDM™ analysis through data-driven, actionable insights. In-house analytical validation results for MSK-IMPACT® powered with SOPHiA DDM™ showed high concordance to the single-site MSK-IMPACT® test, achieving:

    • 99.3% positive percent agreement (PPA) for SNV/Indel detection
    • 94.6%  PPA for copy number variant (CNV) detection
    • 99.4% overall percent agreement (OPA) for microsatellite instability (MSI) detection
    • 98.8% OPA for tumor mutational burden (TMB) detection.

    For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.com, or connect on LinkedIn.

    About SOPHiA GENETICS

    SOPHiA GENETICS (NASDAQ:SOPH) is a cloud-native healthcare technology company on a mission to transform patient care by expanding access to data-driven medicine globally. It is the creator of the SOPHiA DDM™ Platform, which analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.com and connect with us on LinkedIn.

    SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact [email protected] to obtain the appropriate product information for your country of residence. Concordance results based on analytic assessment of RUO products.

    Memorial Sloan Kettering (MSK) has institutional financial interests related to SOPHiA GENETICS.

    SOPHiA GENETICS Forward-Looking Statements:

    This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/sophia-genetics-launches-msk-impact-powered-with-sophia-ddm-at-amp-2024-302312292.html

    SOURCE SOPHiA GENETICS

    Get the next $SOPH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Q&A

    New
    • When was the MSK-IMPACT powered with SOPHiA DDM officially launched?

      SOPHiA GENETICS launched MSK-IMPACT powered with SOPHiA DDM on November 21, 2024, at the Association for Molecular Pathology Annual Meeting.

    • What are the main benefits of using MSK-IMPACT powered with SOPHiA DDM?

      The MSK-IMPACT powered with SOPHiA DDM allows for enhanced detection of somatic mutations, with results achieved in about five days.

    • What is the main mission of SOPHiA GENETICS with the launch of this application?

      SOPHiA GENETICS aims to democratize data-driven medicine globally and expand access to precision oncology, particularly in underserved populations.

    • Who are some of the first organizations to adopt the MSK-IMPACT powered with SOPHiA DDM, and where are they located?

      Early adopters like SOFIVA GENOMICS in Taiwan are utilizing this application to improve localized genomic testing capabilities.

    • What were the concordance results for the MSK-IMPACT powered with SOPHiA DDM based on in-house analytical validation?

      Initial analytical validation results showed high concordance rates: 99.3% for SNV/Indel detection and 94.6% for CNV detection amongst others.

    Recent Analyst Ratings for
    $SOPH

    DatePrice TargetRatingAnalyst
    12/18/2024$11.00Buy
    Craig Hallum
    8/7/2024$10.00 → $5.00Overweight → Equal-Weight
    Morgan Stanley
    6/27/2024$6.00Buy
    Guggenheim
    11/29/2023$8.00Outperform
    RBC Capital Mkts
    7/5/2023$10.00Overweight
    JP Morgan
    1/3/2023$6.00Buy
    BTIG Research
    11/23/2022$2.00Neutral
    Credit Suisse
    2/15/2022$23.00 → $18.00Overweight
    Morgan Stanley
    More analyst ratings

    $SOPH
    Financials

    Live finance-specific insights

    See more
    • SOPHiA GENETICS Reports First Quarter 2025 Results

      BOSTON and ROLLE, Switzerland, May 6, 2025 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Results Revenue was $17.8 million, up 13% year-over-year or 15% on a constant currency basisGross margin was 68.7% on a reported basis and 75.7% on an adjusted basis, up from 65.9% and 70.5% in the prior year period, respectivelyIFRS net loss increased 27% year-over-year to $17.4 million (including a net foreign excha

      5/6/25 6:45:00 AM ET
      $SOPH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SOPHiA GENETICS to Announce Financial Results for First Quarter 2025 on May 6, 2025

      BOSTON and ROLLE, Switzerland, April 22, 2025 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the first quarter 2025 before U.S. markets open on Tuesday, May 6, 2025. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EDT / 2:00 p.m. (14:00) CET. The call will be webcast live on the SOPHiA GENETICS Investor Relations Website. Additionally, a replay will be

      4/22/25 8:00:00 AM ET
      $SOPH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SOPHiA GENETICS Reports Fourth Quarter and Full Year 2024 Results

      BOSTON and ROLLE, Switzerland, March 4, 2025 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for its fourth quarter and fiscal year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights Revenue was $17.7 million, up 4% year-over-year or 6% on a constant currency basis excluding COVID-19-related revenue Gross margin was 68.2% on a reported basis and 74.2% on an adjusted basis, compared to 69.8% and 73.4% in the prior year period, respectivelyOperating loss was $17.4 m

      3/4/25 6:45:00 AM ET
      $SOPH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SOPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Craig Hallum initiated coverage on SOPHiA GENETICS SA with a new price target

      Craig Hallum initiated coverage of SOPHiA GENETICS SA with a rating of Buy and set a new price target of $11.00

      12/18/24 7:54:16 AM ET
      $SOPH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SOPHiA GENETICS SA downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded SOPHiA GENETICS SA from Overweight to Equal-Weight and set a new price target of $5.00 from $10.00 previously

      8/7/24 11:39:17 AM ET
      $SOPH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Guggenheim initiated coverage on SOPHiA GENETICS SA with a new price target

      Guggenheim initiated coverage of SOPHiA GENETICS SA with a rating of Buy and set a new price target of $6.00

      6/27/24 7:51:58 AM ET
      $SOPH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SOPH
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $SOPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SOPHiA GENETICS Reports First Quarter 2025 Results

      BOSTON and ROLLE, Switzerland, May 6, 2025 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Results Revenue was $17.8 million, up 13% year-over-year or 15% on a constant currency basisGross margin was 68.7% on a reported basis and 75.7% on an adjusted basis, up from 65.9% and 70.5% in the prior year period, respectivelyIFRS net loss increased 27% year-over-year to $17.4 million (including a net foreign excha

      5/6/25 6:45:00 AM ET
      $SOPH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SOPHiA GENETICS Announces Expanded Collaboration with AstraZeneca to Accelerate Liquid Biopsy Testing Globally from AACR

      BOSTON and ROLLE, Switzerland, April 28, 2025 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native healthcare technology company and global leader in data-driven medicine, today announced the expansion of its ongoing collaboration with AstraZeneca (NASDAQ:AZN) to accelerate the deployment of MSK-ACCESS® powered with SOPHiA DDM™ globally. Building on the initial collaboration announced in October 2024, this new phase will extend the test's reach to a total of 30 clinical institutions worldwide in 2025. Developed in collaboration with Memorial Sloan Kettering Cancer Cen

      4/28/25 12:00:00 PM ET
      $AZN
      $SOPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • SOPHiA GENETICS to Announce Financial Results for First Quarter 2025 on May 6, 2025

      BOSTON and ROLLE, Switzerland, April 22, 2025 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the first quarter 2025 before U.S. markets open on Tuesday, May 6, 2025. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EDT / 2:00 p.m. (14:00) CET. The call will be webcast live on the SOPHiA GENETICS Investor Relations Website. Additionally, a replay will be

      4/22/25 8:00:00 AM ET
      $SOPH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by SOPHiA GENETICS SA

      SC 13G/A - SOPHiA GENETICS SA (0001840706) (Subject)

      11/13/24 3:31:21 PM ET
      $SOPH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by SOPHiA GENETICS SA (Amendment)

      SC 13G/A - SOPHiA GENETICS SA (0001840706) (Subject)

      2/20/24 4:55:59 PM ET
      $SOPH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by SOPHiA GENETICS SA (Amendment)

      SC 13G/A - SOPHiA GENETICS SA (0001840706) (Subject)

      2/14/24 11:23:25 AM ET
      $SOPH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SOPH
    SEC Filings

    See more
    • SEC Form 144 filed by SOPHiA GENETICS SA

      144 - SOPHiA GENETICS SA (0001840706) (Subject)

      5/19/25 4:21:14 PM ET
      $SOPH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by SOPHiA GENETICS SA

      6-K - SOPHiA GENETICS SA (0001840706) (Filer)

      5/16/25 9:53:25 AM ET
      $SOPH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by SOPHiA GENETICS SA

      6-K - SOPHiA GENETICS SA (0001840706) (Filer)

      5/8/25 2:23:03 PM ET
      $SOPH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SOPH
    Leadership Updates

    Live Leadership Updates

    See more
    • SOPHiA GENETICS Promotes Ross Muken to President and Appoints George Cardoza as Chief Financial Officer

      BOSTON and ROLLE, Switzerland, Nov. 5, 2024 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native software company and leader in data-driven medicine, today announced that Ross Muken, previously Chief Financial Officer ("CFO") and Chief Operating Officer ("COO"), has been promoted to company President, effective November 5, 2024. George Cardoza has been appointed as the company's new CFO. In the newly created role of company President, Ross Muken will oversee SOPHiA GENETICS's global business operations and work even more closely on strategic planning with CEO, Jurgi C

      11/5/24 6:32:00 AM ET
      $SOPH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SOPHiA GENETICS Launches Global Consortium, SOPHiA UNITY, to Accelerate Cancer Research, Drug Development, and Data-Driven Patient Care

      New collective intelligence network to enable the most advanced research in oncology in support of precision medicine BOSTON and ROLLE, Switzerland, May 30, 2024 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced SOPHiA UNITY, a new data-driven consortium designed to accelerate cancer research globally. SOPHiA UNITY aims to bring together leading healthcare institutions to progress a shared goal of furthering cancer research, advancing drug development and supporting data-driven patient care.

      5/30/24 12:19:00 PM ET
      $SOPH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SOPHiA GENETICS Announces Nomination of Lila Tretikov to Board of Directors

      Microsoft's Deputy Chief Technology Officer to be appointed at Annual Shareholders' Meeting BOSTON and LAUSANNE, Switzerland, May 31, 2023 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced the nomination of Lila Tretikov to its Board of Directors. The Board of Directors has proposed the appointment of Tretikov as a member of the board at the Annual General Meeting of Shareholders of SOPHiA GENETICS SA on June 26, 2023. An award-winning powerhouse in the global technology

      5/31/23 9:12:00 AM ET
      $SOPH
      $XYL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Fluid Controls
      Industrials